Ward R Parker, Leeper Nicholas J, Kirkpatrick James N, Lang Roberto M, Sorrentino Matthew J, Williams Kim A
Section of Cardiology, Department of Medicine, University of Chicago Medical Center, 5841 S. Maryland Avenue, MC5084, Chicago, IL 60637, USA.
Int J Cardiol. 2005 Oct 10;104(3):264-8. doi: 10.1016/j.ijcard.2004.10.030.
Patients undergoing vascular surgery are at increased risk for perioperative cardiovascular (CV) complications. Our goal was to determine the effect of preoperative statin therapy on perioperative cardiac and vascular outcomes, and long-term survival in patients undergoing infrainguinal vascular bypass surgery.
We retrospectively reviewed consecutive infrainguinal vascular bypass surgeries on 446 patients performed between 1995-2001 at the University of Chicago Medical Center. Information was collected on preoperative statin and beta-blocker use, baseline characteristics, perioperative cardiac and major vascular complications, and length of stay (LOS). Long-term survival was assessed using the Social Security Death Index (SSDI).
Thirty day perioperative complications included all-cause mortality (2.5%), CV mortality (1.8%), myocardial infarction (MI) (4.7%), stroke (1.1%), and major peripheral vascular complications (12.8%), and the composite of cardiac and vascular complications [combined CV complications] (17.9%). Statin therapy was associated with fewer combined CV complications (6.9% vs 20.1%, p=0.008), and a shorter LOS (6.4 vs 9.7 days, p=0.007). On multivariate logistic regression analysis, adjusting for significant baseline characteristics including beta-blocker use, statin therapy was independently associated fewer combined CV complications (odds ratio (OR) 0.36, 95% confidence interval (CI) 0.14-0.93, p=0.035) and a shorter LOS (OR 1.49, 95% CI 1.14-1.95, p=0.003). In a mean follow up period of 5.5 years, 215 deaths (48%) occurred. Statin therapy was independently associated with improved long-term survival (OR 0.52, 95% CI 0.32-0.84, p<0.004), after adjusting for significant baseline characteristics.
Preoperative statin therapy is associated with fewer combined perioperative cardiac and major vascular complications, a shorter length of stay, and improved long-term survival in patients undergoing infrainguinal vascular bypass surgery.
接受血管手术的患者围手术期心血管(CV)并发症风险增加。我们的目标是确定术前他汀类药物治疗对接受腹股沟下血管搭桥手术患者的围手术期心脏和血管结局以及长期生存率的影响。
我们回顾性分析了1995年至2001年在芝加哥大学医学中心对446例患者进行的连续腹股沟下血管搭桥手术。收集了术前他汀类药物和β受体阻滞剂使用情况、基线特征、围手术期心脏和主要血管并发症以及住院时间(LOS)等信息。使用社会保障死亡指数(SSDI)评估长期生存率。
30天围手术期并发症包括全因死亡率(2.5%)、CV死亡率(1.8%)、心肌梗死(MI)(4.7%)、中风(1.1%)和主要外周血管并发症(12.8%),以及心脏和血管并发症的综合发生率[合并CV并发症](17.9%)。他汀类药物治疗与较少的合并CV并发症相关(6.9%对20.1%,p = 0.008),且住院时间较短(6.4天对9.7天,p = 0.007)。在多因素逻辑回归分析中,在调整包括β受体阻滞剂使用在内的显著基线特征后,他汀类药物治疗与较少的合并CV并发症独立相关(优势比(OR)0.36,95%置信区间(CI)0.14 - 0.93,p = 0.035)以及较短的住院时间(OR 1.49,95% CI 1.14 - 1.95,p = 0.003)。在平均5.5年的随访期内,发生了215例死亡(48%)。在调整显著基线特征后,他汀类药物治疗与改善的长期生存率独立相关(OR 0.52,95% CI 从0.32至0.84,p < 0.004)。
术前他汀类药物治疗与接受腹股沟下血管搭桥手术患者较少的围手术期心脏和主要血管并发症综合发生率、较短的住院时间以及改善的长期生存率相关。